Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences

SAN MARINO, Calif. – May 15 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company’s innovative tumor-targeting technology embodied in its lead product, Rexin-G.